Daily Cosmetic Research Analysis
Key advances span safety, therapeutics, and procedures in aesthetic dermatology. A comprehensive review synthesizes the organ persistence of inhaled cosmetic-relevant nanoparticles (Ag, Au, CuO, ZnO). An investigator-blind randomized trial shows a niacinamide–tranexamic acid–vitamin C–hydroxy acids serum matches 4% hydroquinone efficacy in melasma with better tolerability. A systematic review supports carboxytherapy’s minimally invasive utility across rejuvenation, scars, cellulite, and selected
Summary
Key advances span safety, therapeutics, and procedures in aesthetic dermatology. A comprehensive review synthesizes the organ persistence of inhaled cosmetic-relevant nanoparticles (Ag, Au, CuO, ZnO). An investigator-blind randomized trial shows a niacinamide–tranexamic acid–vitamin C–hydroxy acids serum matches 4% hydroquinone efficacy in melasma with better tolerability. A systematic review supports carboxytherapy’s minimally invasive utility across rejuvenation, scars, cellulite, and selected dermatoses.
Research Themes
- Nanoparticle biokinetics and safety in cosmetics
- Non-hydroquinone depigmenting strategies for melasma
- Evidence for minimally invasive aesthetic procedures (carboxytherapy)
Selected Articles
1. Biokinetics of inhaled silver, gold, copper oxide, and zinc oxide nanoparticles: a review.
Across inhalation studies, silver and gold nanoparticles persist in lungs and secondary organs (liver, spleen, brain/olfactory bulb), with blood kinetics and organ deposition modulated by particle size. Copper oxide shows transient pulmonary retention and zinc oxide increases lung burden after short exposures only. These data highlight organ persistence and potential systemic exposure relevant to nano-enabled cosmetics and occupational settings.
Impact: Synthesizing biokinetic data across four widely used nanoparticles provides an evidence base for exposure limits, labeling, and safer-by-design strategies in cosmetics and personal care aerosols.
Clinical Implications: For aerosolized cosmetic products and occupational handling, minimize inhalable fractions and prioritize larger particle sizes/coatings that reduce organ persistence; integrate size-specific risk communication and post-market surveillance.
Key Findings
- Silver and gold retained in lungs for >2,000 h and >672 h, respectively.
- Size-dependent blood persistence for gold: 4–13 nm elevated ≥672 h; 20–105 nm not elevated.
- Silver increased in liver and spleen up to 2,000 h; both Ag and Au increased in brain and olfactory bulb.
- CuO showed transient lung increase returning to baseline by ~500 h; ZnO increased lung burden after short-term exposure only.
- Overall biodistribution patterns were similar across materials, but Ag and Au showed notable long-term organ persistence.
Methodological Strengths
- Cross-material comparison with size-stratified interpretation.
- Organ- and time-resolved extraction of distribution and clearance parameters from inhalation studies.
Limitations
- Heterogeneous study designs and species limit quantitative synthesis.
- Limited human data and variability in nanoparticle coatings/surface chemistry.
Future Directions: Standardize inhalation exposure protocols and reporting (size, coating, dose metrics) with longitudinal human biomonitoring to inform regulatory thresholds.
The understanding of nanomaterial toxicity is aided by biokinetic information pointing to potential target organs. Silver (Ag), copper oxide (CuO), and zinc oxide (ZnO) are often referred to as soluble materials in the literature. In addition, data suggest gold (Au) nanoparticles to be soluble in the mammalian body. We identified inhalation studies on these materials and extracted data on physicochemical properties, organ distribution, and excretion. Silver and gold were retained in the lung for an extended period (>2,000 and >672 hours, respectively); copper initially increased in lung and then returned to baseline at ∼500 hours. Zinc increased in the lungs after short-term exposure to zinc oxide, but not after prolonged exposure. In blood, silver initially increased after inhalation but then gradually declined over ∼200 hours. Gold was elevated in the blood after exposure to 4, 7, 11, and 13 nm particles (but not particles of 20, 34, and 105 nm) and remained elevated for at least 672 hours after exposure to the 4 and 11 nm particles. Silver increased in the liver and spleen and was still present 2,000 hours post exposure. Gold was elevated in several organs, including the spleen and kidney, for more than 600 hours post exposure, indicating persistence in some organs. Both silver and gold were increased in the brain and olfactory bulb. Overall, we found no large differences in the biodistribution of the four nanomaterials but note that silver and gold were still increased in several organs at the last investigated post-exposure time points.
2. Evaluation of the Efficacy of a Serum Containing Niacinamide, Tranexamic Acid, Vitamin C, and Hydroxy Acid Compared to 4% Hydroquinone in the Management of Melasma.
In a randomized, investigator-blind trial (n=60), a niacinamide–tranexamic acid–vitamin C–hydroxy acids serum achieved comparable melasma improvement to 4% hydroquinone at 3–5 months. The serum showed better tolerability (less erythema) and superior skin hydration/barrier metrics, with significant QoL gains in both groups.
Impact: Provides randomized evidence supporting a non-hydroquinone alternative with comparable efficacy and improved tolerability, addressing safety concerns and regulatory limitations around hydroquinone.
Clinical Implications: Consider multi-ingredient serum as first-line or maintenance therapy for melasma in patients intolerant to hydroquinone or where HQ use is restricted; monitor erythema and skin barrier metrics to tailor regimens.
Key Findings
- Both groups had significant pigmentation reduction at 3 months (p<0.001).
- Higher erythema scores in the hydroquinone-first group; better hydration and barrier function with the serum.
- Quality of life improved significantly in both groups by day 84.
- Melanin density reduction by confocal reflectance microscopy was similar between regimens at 3 and 5 months.
- Serum B3 exhibited better local tolerability and cosmetic acceptability.
Methodological Strengths
- Randomized, investigator-blind design with defined endpoints (MASI/mMASI, QoL, biophysical parameters).
- Objective imaging using confocal reflectance microscopy.
Limitations
- Single-site study with modest sample size (n=60).
- Short-to-intermediate follow-up (3–5 months) without long-term relapse data.
Future Directions: Conduct multicenter, double-blind RCTs with longer follow-up and diverse skin phototypes to assess durability, relapse, and optimal sequencing/maintenance.
INTRODUCTION: Melasma is a common skin condition that remains challenging to treat. Hydroquinone at 4% (HQ4%) is a frequently prescribed depigmenting compound that has been associated with potential side effects. OBJECTIVE: This study assessed the benefit in melasma of an anti-hyperpigmentation serum (Serum B3 containing 5% niacinamide, 1% tranexamic acid, 0.2% of a stabilized form of vitamin C, and different hydroxy acids) compared to HQ4%. MATERIALS AND METHODS: In a single-site, investigator-blind, randomized study, 60 females aged between 20 and 50 years with facial melasma received Serum B3 for 5 months (Group 1) or HQ4% for 3 months followed by Serum B3 for an additional2 months (Group 2). Endpoints were Melasma Area and Severity Index (MASI), modified MASI (mMASI), Investigational Global Assessment, erythema, clinical cutaneous parameters, and safety. Subjects assessed quality of life (QoL) and cosmetic acceptability. Confocal reflecting microscopy was performed. RESULTS: A significant (p < 0.001) reduction in pigmentation was seen in both groups after 3 months. A higher erythema score was noted in Group 2. Hydration and skin barrier function performed better in Group 1. QoL significantly (p < 0.001) improved in both groups after 84 days. Serum B3 was tolerated better than HQ, and subjects appreciated Serum B3. Melanin density reduction was similar for both groups after 3 and 5 months. CONCLUSION: Serum B3 used for 5 months and HQ4% applied for 3 months, followed by a 2-month use of Serum B3, had a similar efficacy profile, with Serum B3 having a better local tolerance and patient acceptability.
3. Carboxytherapy in Dermatologic Surgery and Aesthetic Medicine: Current Knowledge and Future Perspectives-A Systematic Review.
This systematic review (41 studies) suggests carboxytherapy is a safe, well-tolerated, minimally invasive option for facial rejuvenation, cellulite, scars, and selected conditions (e.g., alopecia, vitiligo, chronic diabetic wounds). Mechanisms include improved oxygenation, angiogenesis, and enhanced perfusion/lymphatic drainage.
Impact: Consolidates a fragmented evidence base to guide patient selection, indications, and expectations for a widely used but variably standardized aesthetic procedure.
Clinical Implications: CXT can be considered for patients seeking minimally invasive rejuvenation or adjunctive therapy for scars/cellulite, with counseling on variable protocols and need for multiple sessions; standardization and RCT data remain limited.
Key Findings
- Forty-one studies were synthesized: 14 on facial rejuvenation, 17 on cellulite/scars/fat, and 10 on other conditions.
- CXT generally demonstrated anti-aging benefits and potential efficacy in alopecia, lichen planopilaris, vitiligo, chronic diabetic wounds, TMJ arthralgia, and lipedema.
- Mechanistic rationale includes Bohr effect-driven oxygenation, angiogenesis, improved perfusion, and lymphatic drainage.
- Treatment was typically well tolerated with a minimally invasive profile.
Methodological Strengths
- PRISMA-based systematic search terms and predefined inclusion of original studies.
- Broad coverage across aesthetic and medical dermatology indications.
Limitations
- Heterogeneous protocols and outcomes; few randomized controlled trials; no meta-analysis.
- Single-database (PubMed) search may miss studies; potential publication bias.
Future Directions: Develop standardized dosing/device parameters and conduct multicenter RCTs with core outcome sets to enable meta-analysis and cost-effectiveness evaluations.
BACKGROUND AND OBJECTIVE: Carboxytherapy (CXT) is a minimally invasive procedure based on percutaneous or subcutaneous microinjections of carbon dioxide. Due to the Bohr effect, it influences the hemoglobin dissociation curve, improving tissue oxygenation, angiogenesis, facilitating vascular perfusion, and lymphatic drainage. Recent evidence suggests unconventional applications in dermatologic surgery and aesthetic medicine; these are focused with the present review. METHODS: A systematic review was conducted by searching the PubMed library from January 2018 to July 2023, using the terms "Dermatologic Surgery, Aging, Rejuvenation, Scars, Cellulite, Alopecia, AND Carboxy therapy." Eligibility criteria included original studies aimed at discussing CXT in dermatologic surgery and aesthetic medicine. RESULTS: The final synthesis included 41 articles distinguished by topic into studies on the role of CXT in facial rejuvenation ( n .14), in cellulite, scars and fat deposits treatment ( n .17), and other pathologic conditions ( n .10). Overall, CXT is an effective antiaging treatment. Furthermore, CXT may play a role in several pathologic conditions including alopecia, lichen planopilaris, vitiligo, chronic diabetic wounds, temporomandibular arthralgia, and lipedema. CONCLUSION: CXT, by promoting tissue oxygenation and microvascular and vascular perfusion, appears to have promising indications for several aesthetic and pathologic conditions, potentially offering satisfactory results with a minimally invasive, safe, and well-tolerated treatment.